NEW YORK, NY – May 13, 2015
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 2015 Marcum Microcap Conference on Wednesday, May 27, 2015 at 3:30 p.m. ET in the Winter Garden room at the Grand Hyatt New York.
Dr. Missling’s presentation will include an overview of Anavex’s ongoing Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS in Alzheimer’s patients, with expected preliminary data in Q3 2015. Dr. Missling will also discuss the Company’s other development programs.
Management plans to be available for one-on-one meetings with members of the investment community at the conference. Attendees are invited to contact Anavex at firstname.lastname@example.org to request a meeting with management.
Hosted by national accounting and advisory firm Marcum LLP, the Marcum Microcap Conference is being held May 27 to 28, 2015 in New York City. This event attracts fund managers and high net worth investors who focus on small cap equities. Over 2,000 participants from all segments of the microcap market are expected to participate.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases, pain and various types of cancer. The Company’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently being evaluated in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and has successfully completed a Phase 1 study with a clean data profile. Preclinical studies demonstrate its potential to halt and/or reverse the course of Alzheimer’s disease. The drug combination, ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Recent positive preclinical data indicates that ANAVEX 2-73 also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties, indicating its potential to treat additional CNS disorders, including epilepsy and others. Further information is available at www.anavex.com.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: email@example.com
Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: firstname.lastname@example.org www.anavex.com